Progressive systemic sclerosis (PSS), also known as scleroderma, is a complex disease that involves multiple organ systems. Patients with PSS can pose significant challenge for an anesthesiologist. As the disease progresses, profound pulmonary, gastrointestinal, renal, cardiac, and musculoskeletal system changes occur. An anesthesiologist should understand these complex pathophysiological processes in order to minimize potential risks including aspiration and other pulmonary complications. In addition, the potential for reduced renal function and intraoperative hypothermia-induced vasospasm must be considered. Meticulous preoperative assessment and diagnostic evaluation along with prudent intraoperative management is critical to minimize potential postoperative complications.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A new effLuc/Kate dual reporter allele for tumour imaging in mice.
Dis Model Mech
January 2025
Laboratory Genes and Disease, Department of Laboratory Medicine, Medical University of Vienna (MUW), Vienna, Austria.
Genetically engineered mouse models (GEMMs) are instrumental for modelling local and systemic features of complex diseases such as cancer. Non-invasive, longitudinal cell detection and monitoring in tumors, metastases and/or the micro-environment is paramount to achieve a better spatiotemporal understanding of cancer progression and to evaluate therapies in preclinical studies. Bioluminescent and fluorescent reporters marking tumor cells or their microenvironment are valuable for non-invasive cell detection and monitoring in vivo.
View Article and Find Full Text PDFDevelopment and Evaluation in Rat and Monkey of a Candidate Homochiral Radioligand for PET Studies of Brain Receptor Interacting Protein Kinase 1: [F]()-1-(5-(3-Fluorophenyl)-4,5-dihydro-1-pyrazol-1-yl)-2,2-dimethylpropan-1-one.
ACS Chem Neurosci
January 2025
Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, 10 Center Drive, Bethesda, Maryland 20892, United States.
Receptor interacting protein kinase 1 (RIPK1) crucially upregulates necroptosis and is a key driver of inflammation. An effective PET radioligand for imaging brain RIPK1 would be useful for further exploring the role of this enzyme in neuroinflammation and for assisting drug discovery. Here, we report our progress on developing a PET radioligand for RIPK1 based on the phenyl-1-dihydropyrazole skeleton of a lead RIPK1 inhibitor, GSK'963.
View Article and Find Full Text PDFLC-STH-13 ameliorates the progression of SLE in MRL/lpr mice by inhibiting the TLR9/NF-κB signaling pathway.
Food Funct
January 2025
School of Life Sciences, Nanchang University, Nanchang 330031, China.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease often treated with glucocorticoids, which can lead to complications such as osteoporosis and an increased infection risk. Hence, identifying safe and effective treatment strategies is crucial. has shown promise in improving immune disorders.
View Article and Find Full Text PDFThe 2024 APLAR Consensus on the Management of Lupus Nephritis.
Int J Rheum Dis
January 2025
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
The APLAR has published a set of recommendations on the management of systemic lupus erythematosus (SLE) in 2021. The current consensus paper supplements and updates specifically the treatment of lupus nephritis (LN) according to two rounds of Delphi exercise from members of the APLAR SLE special interest group, invited nephrologists, histopathologists, and lupus nephritis patients. For initial treatment of LN, we recommend a combination of glucocorticoids (GCs) with cyclophosphamide (CYC), mycophenolate mofetil (MMF), or the calcineurin inhibitors (CNIs) as first-line options.
View Article and Find Full Text PDFMetastasis-directed therapy in oligometastatic and oligoprogressive renal cell carcinoma.
Curr Opin Urol
December 2024
Division of Urologic Oncology.
Purpose Of Review: This review addresses the evolving role of metastasis-directed therapy (MDT) in the management of oligometastatic and oligoprogressive renal cell carcinoma (RCC). With advances in both surgical techniques and stereotactic ablative radiotherapy (SABR), it is timely to explore how MDT can improve patient outcomes in these distinct disease states. The review highlights the potential of MDT to delay systemic therapy and improve quality of life while noting the lack of randomized clinical trial data guiding its use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!